24,20 €
Deine Einschätzung
Agios Pharmaceuticals Inc. Aktie
Was spricht für und gegen Agios Pharmaceuticals Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Agios Pharmaceuticals Inc. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | -1,63 % | 4,31 % | 4,31 % | -30,86 % | 4,31 % | -5,47 % | -35,38 % |
| Ironwood Pharmaceuticals | 0,00 % | -7,18 % | 10,53 % | -23,29 % | 26,32 % | -71,19 % | -65,00 % |
| Novocure Ltd | 3,61 % | 14,17 % | 16,78 % | -54,43 % | 12,66 % | -84,98 % | -90,84 % |
| Iovance Biotherapeutics Inc. | -5,37 % | -2,10 % | 8,83 % | -69,98 % | -11,40 % | -63,36 % | -94,92 % |
Kommentare
News
Here's Why Shares in Agios Pharmaceuticals Popped Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) soared by more than 18% as of 11 a.m. today. The move follows the company's receipt of approval from the Food and Drug Administration (FDA) for AQVESME
Why Shares in Agios Pharmaceuticals Got Crushed Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) crashed by 50% by noontime today. The move comes as the market digests a mixed set of topline results from its Phase 3 trial (RISE UP) of its sickle
Agios (AGIO) Q2 Revenue Jumps 45%
Agios Pharmaceuticals (NASDAQ:AGIO), a biotechnology company focused on therapies for rare blood disorders, released its second quarter 2025 earnings on July 31, 2025. The headline was a notable



